These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2943916)

  • 1. [Thrombosis in various diseases: myeloproliferative disorders].
    Niikura H
    Nihon Rinsho; 1986 May; 44(5):1144-52. PubMed ID: 2943916
    [No Abstract]   [Full Text] [Related]  

  • 2. [Phospholipids and platelet procoagulant activity in myeloproliferative syndromes].
    Martínez E; César J; Navarro JL; Mercado A; Pardo A; García Avello A; García Frade J
    Sangre (Barc); 1985; 30(1):22-7. PubMed ID: 4039850
    [No Abstract]   [Full Text] [Related]  

  • 3. Does the beta TG/PF4 ratio have any value in myeloproliferative diseases?
    Viero P; Cortelazzo S; Barbui T
    Thromb Haemost; 1984 Jul; 51(3):411. PubMed ID: 6208631
    [No Abstract]   [Full Text] [Related]  

  • 4. The value of beta TG/PF4 ratio in patients with high platelet count.
    Fabris F; Luzzatto G; Girolami A
    Thromb Haemost; 1985 Apr; 53(2):288-9. PubMed ID: 2410998
    [No Abstract]   [Full Text] [Related]  

  • 5. Platelet-specific proteins in myeloproliferative disorders.
    Luzzatto G; Cella G
    Acta Haematol; 1992; 87(4):216-7. PubMed ID: 1387757
    [No Abstract]   [Full Text] [Related]  

  • 6. Influence of antiplatelet drugs on beta tg and PF4 levels in patients with transient ischemic attacks.
    Fabris F; Randi ML; Casonato A; Dal Bo Zanon R; Manzoni S; Tonin P; De Zanche L; Girolami A
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():263-5. PubMed ID: 2408445
    [No Abstract]   [Full Text] [Related]  

  • 7. [Determination of platelet activation products (platelet factor IV and beta-thromboglobulin) in a group of workers with long-term exposure to carbon disulfide].
    Craveri A; Lanfredini M; Tornaghi G; Frangione A; Milella AM; Ranieri R; Tonali M; Gatti L; Franco G; Moia M
    G Clin Med; 1980 Nov; 61(11):812-21. PubMed ID: 6165639
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hemostasis disorders and their treatment in patients with chronic myeloproliferative diseases].
    Sidorova LD; Arkhipov BF; Degtiareva MM; Barkagan LZ
    Ter Arkh; 1981; 53(9):91-5. PubMed ID: 7302866
    [No Abstract]   [Full Text] [Related]  

  • 9. Platelet specific proteins in Bernard-Soulier syndrome.
    Devaraj R; Prowse C; Dawes J; Toolis F
    Thromb Haemost; 1979 Dec; 42(4):1349. PubMed ID: 94471
    [No Abstract]   [Full Text] [Related]  

  • 10. PF 4 versus beta TG as evidence for platelet activation in myeloproliferative disorders.
    Luzzatto G; Fabris F; Mazzucato M; Girolami A
    Scand J Haematol; 1985 Sep; 35(3):299-304. PubMed ID: 2414843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Warning: platelet factor 4, beta-thromboglobulin and thromboxane in donor's plasma units.
    Stratta P; Canavese C; Peiretti F; Vallauri P; Vercellone A
    Thromb Haemost; 1983 Feb; 49(1):61. PubMed ID: 6189235
    [No Abstract]   [Full Text] [Related]  

  • 12. Platelet activation and allergic asthma.
    Gresele P; Todisco T; Merante F; Nenci GG
    N Engl J Med; 1982 Mar; 306(9):549. PubMed ID: 6173752
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunological localisation of beta-thromboglobulin and platelet factor 4 in human megakaryocytes and platelets.
    McLaren KM; Pepper DS
    J Clin Pathol; 1982 Nov; 35(11):1227-31. PubMed ID: 6183294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-specific proteins in patients with transient ischemic attacks. (Effects of anti-platelet drugs).
    Fabris F; Randi ML; Crociani ME; Manzoni S; Tonin P; De Zanche L; Cella G; Girolami A
    Ric Clin Lab; 1983; 13(4):437-42. PubMed ID: 6197742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between plasma levels of the factor VIII complex and platelet release products (beta-thromboglobulin and platelet factor 4) in children with the hemolytic-uremic syndrome.
    Appiani AC; Edefonti A; Bettinelli A; Cossu MM; Paracchini ML; Rossi E
    Clin Nephrol; 1982 Apr; 17(4):195-9. PubMed ID: 6176380
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma beta-thromboglobulins and platelet factor 4 during the normal menstrual cycle.
    Motomiya T; Yamazaki H
    Nihon Ketsueki Gakkai Zasshi; 1981 Feb; 44(1):193-5. PubMed ID: 6171983
    [No Abstract]   [Full Text] [Related]  

  • 17. Does the beta-TG/PF4 ratio have any value?
    Arocha-Piñango CL; Ojeda A
    Thromb Haemost; 1983 Apr; 49(2):147. PubMed ID: 6191402
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of aspirin on platelet 5-hydroxytryptamine and beta-thromboglobulin plasma levels in patients with myeloproliferative diseases.
    Viero P; Cortelazzo S; Bassan R; Barbui T
    Thromb Haemost; 1982 Oct; 48(2):125-6. PubMed ID: 6184841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of the radioimmunological determination of beta-thromboglobulin and platelet factor 4].
    Schernthaner G; Silberbauer K; Mühlhauser I; Willvonseder R
    Acta Med Austriaca Suppl; 1979; 6():375-9. PubMed ID: 95543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pressure excursions on human platelets. In vitro studies on betathromboglobulin (beta-TG) and platelet factor 4 (PF4) release and on platelet sensitivity to ADP-aggregation.
    Torsellini A; Becucci A; Citi S; Cozzolino F; Guidi G; Lombardi V; Vercelli D; Veloci M
    Haematologica; 1982; 67(6):860-6. PubMed ID: 6186580
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.